REPL shares surge 137% premarket after the FDA's panel of outside advisers voted to back results from a trial studying the company's drug fo
REPL shares surge 137% premarket after the FDA's panel of outside advisers voted to back results from a trial studying the company's drug for a type of skin cancer. REPL seeks accelerated approval for RP1 in combination with BMY's Opdivo in advanced melanoma in patients whose tumors grew despite prior treatment, with a decision expected by August 2
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.